Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.
| Revenue (Most Recent Fiscal Year) | $14.00M |
| Net Income (Most Recent Fiscal Year) | $-130.39M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 42.41 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 133.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -179.28% |
| Net Margin (Trailing 12 Months) | -176.04% |
| Return on Equity (Trailing 12 Months) | -296.78% |
| Return on Assets (Trailing 12 Months) | -49.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 6.19 |
| Inventory Turnover (Trailing 12 Months) | 0.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.44 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 87.00M |
| Free Float | 63.94M |
| Market Capitalization | $2.94B |
| Average Volume (Last 20 Days) | 1.94M |
| Beta (Past 60 Months) | 0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |